Fabrication and In Vitro Evaluation of Silk Fibroin-Folic Acid Decorated Paclitaxel and Hydroxyurea Nanostructured Lipid Carriers for Targeting Ovarian Cancer Cells: A Double Sword Approach

    March 2023 in “ Journal of drug delivery science and technology ”
    Praharsh Kumar Mandadhi Rajendra, Bala Sai Soujith Nidamanuri, Akey Krishna Swaroop, Janani Selvam Krishnamurali, Anjali Puthusserikkunnu Balan, Jubie Selvaraj, R. Raman, H.N. Shivakumar, Murthannagari Vivek Reddy, N Jawahar
    TLDR The new drug carriers show promise for better targeting and treating ovarian cancer.
    This study addresses the limitations of conventional chemotherapy for ovarian cancer by developing paclitaxel (PTX) and hydroxyurea (HU) loaded nanostructured lipid carriers (NLCs) decorated with a silk fibroin-folic acid conjugate (SF-FA). These SF-FA NLCs were characterized and tested on SKOV-3 ovarian cancer cells, showing smaller particle size, good entrapment efficiency, and sustained drug release. The NLCs demonstrated superior cytotoxicity, cell cycle arrest at G0/G1 and S phases, and apoptotic activity compared to pure paclitaxel. The scratch assay confirmed better inhibition of cell proliferation, suggesting that PTX and HU SF-FA NLCs are promising for targeted ovarian cancer therapy.
    View this study on sciencedirect.com →